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Metastatic melanoma is one of the deadliest of skin cancers and is increasing in incidence. Since current treatment regimens
are ineﬀective at controlling and/or curing the disease, novel approaches, such as immunotherapy, for treating this malignant
disease are being explored. In this review, we discuss potential melanoma antigens (Ags) and their role in utilizing the HLA class
II pathway to elicit tumor Ag-speciﬁc CD4+ T cell responses in order to eﬀectively induce long-lasting CD8+ antitumor memory.
We also discuss the role of endolysosomal cathepsins and Gamma-Interferon-inducible Lysosomal Thiol reductase (GILT) in Ag
processing and presentation, and at enhancing CD4+ T cell recognition of melanoma cells. This review also summarizes our
current knowledge on GILT and highlights a novel mechanism of GILT-mediated immune responses against melanoma cells. At
the end, we propose a strategy employing GILT in the development of a potential whole cell vaccine for combating metastatic
melanoma.
Copyright © 2009 D. L. Norton and A. Haque. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Rising incidences of melanoma make it one of the rapidly
growing cancers plaguing western populations. It is the
8th leading cause of cancer deaths in the US with an
estimated 68,720 new cases diagnosed in 2009 [1–5].
Current melanoma therapies such as surgery, radiation,
and chemotherapy are eﬀective against early stage localized
tumors [1–4]. However, these therapies fail to treat and
cure large malignant tumors which generally prove to be
fatal. These therapies are also extremely damaging and toxic
to the patient, suggesting a need for the development of
new therapies. Immunotherapy is an extremely attractive
therapy against melanoma as it is associated with a high
cure rate and could have little to no potential side eﬀects
while providing long term protection against a recurrence of
the disease. Long-lasting immune responses and protection
against melanoma is largely dependent upon the activation
of helper CD4+ and cytotoxic CD8+ T cells [6, 7]. Current
studies suggest that malignant melanomas can constitutively
express Human Leukocyte Antigen (HLA) class I and II
molecules which are essential for the stimulation of CD8+
and CD4+ T cells [8, 9]. Also, strong CD8+ and CD4+ T
cell immune memory responses to the presentation of tumor
antigens (Ags) seem to require processing and crosspresen-
tation by professional antigen presenting cells (APCs) [10,
11]. A key factor that distinguishes APCs such as dendritic
cells (DC), macrophages, and B cells from melanoma cells
is the fact that APCs express an abundance of adhesion
and costimulatory molecules (e.g., CD80 and CD86) that
allow for prolonged interaction between HLA complexes
and T cells [12]. In the case of the HLA class II pathway,
Ag processing and presentation by APCs rely heavily on
proteases in intracellular endosomes and lysosomes which
give rise to a large array of peptides for display to CD4+ T
cells.
Inside APCs, reactions crucial to the processing of Ags
and large peptides such as proteolysis and the reduction of
disulﬁde bonds are highly eﬀective; ultimately giving rise to
HLA class II-peptide complexes available for presentation
to T cells. A potential problem that aﬄicts HLA class II
presentation is the spontaneous cysteinylation of peptides2 Journal of Oncology
andAgsbothinvitroandinvivo[11,13].Thiscysteinylation
is due to interaction with cystine within biological ﬂuids
[10, 11]. We have previously shown that melanoma cells
expressing HLA class II molecules fail to eﬀectively process
oxidized or cysteinylated peptides [11]. This disruption in
processing of peptides ultimately ends with a modiﬁed
epitope presentation to CD4+ T cells and a lack of an
immune response. We have also shown that the enzyme
Gamma-IFN-inducible Lysosomal Thiol reductase (GILT) is
highly expressed in professional APCs, but absent or slightly
expressed in human melanomas [11]. The expression of
GILT has been found to restore the processing of cysteiny-
lated melanoma tumor Ags and CD4+ T cell recognition
of tumors cells [11]. A lack of GILT in melanoma cells has
been found to alter the processing of both endogenous and
exogenous proteins/peptides within the tumor cells [14].
The absence of GILT within melanomas also allows for a
diﬀerential display of antigenic peptides which results in an
escape from the class II pathway of immune recognition.
The reduction of disulﬁdes is important for the processing of
tumor Ags such as tyrosinase, gp-100, Mart-1, and NY-ESO-
1, which all contain a large number of cystiene residues [15–
18]. Thus, the expression of GILT is needed in melanoma
cells and APCs for reductive processing and presentation of
these melanoma Ags to T cells.
Professional APCs express high levels of HLA class II
molecules and GILT which are crucial for Ag processing
and presentation to CD4+ T cells. While many studies have
focused on increasing the immunogenicity of melanoma
cells, one of the most eﬃcient methods is to have the tumor
cells present their own Ags and peptides [10, 11, 19, 20]. We
and others have shown that melanoma tumors do indeed
have HLA class II molecules, but these molecules are often
expressed at low levels [10, 11, 21, 22]. Thus, this review will
focus on GILT; its function in improving Ag processing and
presentation within melanoma cells and we will discuss the
implications it may have in the treatment of patients with
metastatic melanoma.
2. Potential Self Ags for Use in
Melanoma Immunotherapy
Melanoma cells express a wide variety of self proteins
that have antigenic properties and could induce potent
immunogenic responses against the tumor. The most widely
known and expressed melanoma Ags are MART-1, NY-
ESO-1, gp100, and tyrosinase. These Ags have been shown
to elicit both cytotoxic CD8+ and helper CD4+ T cell
responses. Each of these Ags has been extensively stud-
ied, and potential immunodominant epitopes have been
identiﬁed for the development of vaccine reagents against
metastatic melanoma. In this section, we will discuss these
self Ags and their antigenic determinants that may elicit both
CD4+ and CD8+ T cell responses against HLA class I and II
expressing melanoma cells.
MART-1, also known as Melan-A, is a commonly
detected melanoma-associated Ag. Since its discovery in
1994, MART-1 has been the focus of the development of
strategies to target melanoma via the immune system [23,
24]. A number of naturally occurring HLA class I and II
epitopes have been identiﬁed from MART-1 and have since
become the basis of many clinical trials. One such peptide
is the class I-restricted MART-127–35 (AAGIGILTV) which is
capable of eliciting an antitumor CD8+ T cell response [24].
Two slightly longer versions of this peptide: Melan-A27–40
(AAGIGILTVILGVL) and Melan-A25–36 (EEAAGIGILTVI),
have been shown to elicit CD4+ T cell responses [22].
These particular peptides are extremely attractive targets for
inducing antimelanoma immunity as they can be further
processed into the immunogenic class I-restricted peptide
which is capable of eliciting cytotoxic T cell (CTL) responses.
Similarly, the HLA-DR4-restricted peptide MART-151–73
(RNGYRALMDKSLHVGTQCALTRR) has been shown to
induce high CD4+ T cell responses in conjunction with the
class I peptide MART-127–35 within melanoma patients [25].
The ability of each of these peptides to generate eﬀective
CD4+ and CD8+ antitumor immune responses makes them
attractive targets for treating melanoma.
NY-ESO-1 is a tumor-associated Ag that is found in a
multitude of cancers such as melanoma, breast, prostate, and
lung [26]. Over the past decade, NY-ESO-1 has become one
of the many targets for potential immunotherapy against
melanoma. Within melanoma cells, a number of HLA class
I and HLA class II-restricted NY-ESO-1 epitopes have been
identiﬁed as immunodominant epitopes. NY-ESO-160–72
(APRGPHGGAASGL) is a relatively long, naturally occur-
ring peptide that is restricted to HLA-B7 molecules [27],
which is commonly expressed in all populations regardless
of geographic location [28, 29]. The HLA class II-restricted
peptide NY-ESO-1116–135 (LPVPGVLLKEFTVSGNILTI) has
also been shown to be capable of stimulating cytokine
production by CD4+ T cells [18]. It is interesting to note
that NY-ESO-1116–135 peptide-speciﬁc T cells are also able
to recognize B-lymphoblastoid cells pulsed with the whole
protein [18]. This suggests that NY-ESO-1 can be naturally
processed by tumors as well as professional APCs, and then
presented via the class II pathway for the induction of Ag-
speciﬁc antitumor immunity. These two peptides: NY-ESO-
160–72 and NY-ESO-1116–135, could be combined in therapy to
cause regression of melanoma as well as other tumors.
Gp100, also known as pmel17, is a melanosomal matrix
protein involved in the synthesis of melanin. It was originally
identiﬁed as a potential tumor Ag after tumor inﬁltrating
lymphocytes were seen in cancer regressing melanoma
patients [30]. Gp100 has since been studied for its potential
uses in diﬀerent immunotherapies for tumor regression
and establishing lasting antitumor memory. Many Gp100
epitopes have been predicted for prospective use in the
treatment of melanoma, one of which is the gp10044–59
(WNRQLYPEWTEAQRLD) epitope. Gp10044–59 has been
previously shown to stimulate CD4+ T cells [31], and
has also been reported as a natural epitope [32]. Another
potential peptide is the HLA-A2 restricted gp100154–162
(KTWGQYWQV)epitopewhichiscapableofeliciting CD8+
T cell responses when presented by mature DC [33]. Since
both APCs and tumors naturally process and present these
tumor-associated peptides to both CD8+ and CD4+ T cells,Journal of Oncology 3
they could be used in devising new immunotherapeutics
against metastatic melanoma.
Tyrosinase is a type 1 transmembrane protein that is
often found in melanoma. Tyrosinase has previously been
studied and has been found to encode multiple epitopes that
are recognized by CD4+ T cells. Of these multiple epitopes,
tyrosinase56–70 (QNILLSNAPLGPQFP) has been suggested
as a possible immunodominant epitope and shown to elicit
CD4+ T cell responses [33]. Another tyrosinase peptide
is the HLA-A restricted tyrosinase243–251 (KCDICTDEY)
which is unique in the sense that it contains two cysteine
residues, since many HLA class I epitopes identiﬁed have
few to no cysteine residues [34]. Tyrosinase243–251 is naturally
processed and is recognized by CTLs [34], making it an
attractive target in conjunction with tyrosinase56–70 for
developing treatments against malignant melanoma.
MART-1, NY-ESO-1, gp100, and tyrosinase contain
multiple cysteine residues which are susceptible to oxi-
dation reaction. GILT expression in melanoma cells may
help process these Ags, or their cysteinylated peptides,
to functional epitopes for delivery to T cells via HLA
molecules. Immunodominant epitopes from Ags expressed
by melanoma tumors could be the focus of therapeutics to
aid in the treatment of melanoma patients. One potential
treatment option could be the development of a variety of
vaccines to challenge the patient’s immune system. Possible
strategies may include whole cell vaccines, various dendritic
cell vaccines, and peptide vaccines where HLA class I and II-
restricted immunodominant epitopes from multiple tumor
Ags are used. These vaccine materials are few examples that
could stimulate the immune system via the HLA class I and
II pathways leading to tumor regression and induction of
lasting antitumor immune memory.
3. Importance of HLA ClassII Pathway in
DirectAg Presentationby Melanoma Cells
HLA class II molecules can bind both endogenously and
exogenously derived antigenic peptides and stimulate CD4+
T cells [35]. In order for CD4+ T cells to recognize these
Ags/peptides, they must ﬁrst be processed by APCs or tumor
cells, loaded onto the HLA class II dimer, and transported
to the cell surface. Professional APCs express high levels of
HLA class II proteins and are eﬃcient in delivering processed
peptides to CD4+ T cells [36]. HLA class II αβ heterodimers
are synthesized within the endoplasmic reticulum (ER) of
APCs and form a complex with the glycoprotein invariant
chain (Ii) which prevents premature peptide loading into
class II molecules [37–39]. Ii also facilitates the transport
of HLA class II αβ heterodimers to the endolysosomal
compartments via the trans-Golgi network [40]. Once inside
the endolysosomal compartment, acidic proteases, such as
cathespins S and L, begin to degrade Ii into smaller interme-
diatepeptideswiththeendresultbeingtheclassII-associated
Ii peptide (CLIP) [41–44]. CLIP blocks the peptide binding
g r o o v eu n t i li ti sr e m o v e d ,e ﬀectively preventing premature
peptide loading. Processing of Ags also occurs during this
time by other acidic proteases such as cathepsins D and B
[41, 45, 46]. These acidic proteases unfold, cut, and splice
both endogenous and exogenous Ags into smaller peptides.
The nonclassical molecule, HLA-DM, has a unique role
within the class II pathway [47, 48]. HLA-DM chaperones
the removal of CLIP from the peptide binding grove and
aﬀects the peptide repertoire by inﬂuencing high aﬃnity
peptides to bind to the peptide binding pouch, eﬀectively
forming a HLA class II-peptide complex [35, 47, 48]. The
HLA class II-peptide complex is then transported to the
cell surface for presentation to CD4+ T cells. Upon TcR
interaction with the HLA class II-peptide complex, members
of the B7 family (CD80/CD86) interact with CD28 on the T
cell surface. This interaction lowers the signaling threshold
needed for stimulation and cytokine production [49, 50].
Upon stimulation, CD4+ T cells can help direct an immune
response against the targeted Ag(s). Since melanoma cells
express their own tumor Ags that contain class II-restricted
epitopes, activation of the HLA class II pathway could
induce an eﬀective antitumor immune response against the
malignant disease.
Current animal model studies indicate that established
small tumors can be reduced by actively immunizing the
host against tumor cell Ags. The immunization of animals
with speciﬁc tumor cells transduced to express HLA class
II and the costimulatory molecules CD80/CD86 have been
shown to halt tumor progression and establish an immune
memory against the speciﬁc tumor [12]. The antitumor
response elicited by the vaccines is dependent on CD4+ T
cell activation through HLA class II molecules on both APCs
and tumor cells. Since melanoma cells express HLA class II
molecules,theycanactasAPCsandpresenttheirowntumor
Ags to CD4+ T cells. CD4+ T cells, which recognize these
tumor epitopes, could be activated and would then be able
to recruit professional APCs as well as CTLs and NK T cells.
Thus, by inducing melanoma tumors to present their own
Ags, the host would be able to naturally reduce the tumor
without the side eﬀects of current therapies.
4.AcidicProteasesSuchAsCysteinyland
Aspartyl Cathepsins Are Important for
Ag Processing and HLA Class II Presentation
by Melanoma Cells
Ag processing and presentation are important for successful
CD4+ T cell stimulation. Intracellular proteases such as
cysteinyl and aspartyl cathepsins (Cat S, B, D,) are essential
for degradation of endogenous and exogenous Ags, and each
performs an important role in the processing of peptides
for presentation (Figure 1). Cathepsin B can also aid in
Ag presentation by upregulating class II protein expression
in APCs [41, 46]. Cathepsin D has a very unique role in
Ag presentation by degrading and splicing Ags into short
peptides [45, 46]. Peptides cannot be loaded into the class
II binding grove until CLIP is removed by the nonclassical
molecule, HLA-DM [48]. After HLA-DM has successfully
chaperoned the insertion of a high-aﬃnity peptide, stable
HLA class II-peptide complexes can then be presented on the















Figure 1: Norton and Haque.
We have previously shown that the active forms of cys-
teinyl and aspartyl cathepsins are upregulated in melanoma
cells transfected with GILT [46]. Our laboratory has also
demonstrated that GILT colocalizes with Cat D and B,
further suggesting that GILT is crucial for Ag processing
and presentation via the class II pathway [46]. This also
suggests that melanoma cells expressing GILT may be able
to process more tumor Ags and produce functional epitopes
for class II presentation. Our current studies suggest that the
protease activities of cathepsin S, B, and D are increased in
GILT-expressing melanoma cells as compared to melanoma
cells lacking GILT (unpublished data). This upregulation of
acidic proteases raises the possibility that more functional
epitopes could be generated for HLA class II presentation
by melanoma cells. Since melanoma cells express many self
proteinsthatareantigenic,introductionofGILTinthesecells
could be beneﬁcial for generating a pool of functional tumor
peptides. This would then lead to CD4+ T cell recognition
and ultimately tumor destruction by immune eﬀector cells
such as CTL and NK T cells.
5. The Insertion of GILT into Melanoma Cells
Restores CD4+TCellRecognition
GILT is a lysosomal reductase, abundantly expressed in
professional APCs, but absent or undetectable in melanoma
cells and other tumors [52]. However, GILT can be induced
in melanoma and other tumor cells when treated with
IFNγ [53]. Within APCs, GILT is found in its proform
in early endosomes, while the mature form is found in
multivesicular late endosomes and multilaminar lysosomes
[54]. GILT is active at low pH and catalyzes the breaking of
disulﬁde bonds, making Ags/peptides susceptible to degra-
dation by acidic cathepsins [55, (Figure1)]. Experimental
evidence suggests that GILT is required for processing
of posttranslationally modiﬁed/oxidized epitopes for HLA
class II-mediated presentation [56]. We have previously
reported that GILT is regulated by STAT-1 instead of class II
transactivator (CIITA) which is important for the activation
of HLA class II gene loci [57].
GILT expression has been shown to enhance Ag pro-
cessing and CD4+ T cell recognition in vitro and in vivo
[11, 46, 56]. An alteration in the expression of tumor
Ags or disturbance in the HLA presentation pathway may
be the reason tumor cells evade immunogenic ablation
[58]. Thus, the restoration of the HLA class II peptide
presentation pathway in melanoma may enhance the ability
of the tumor cells to promote immunological destruction
and surveillance. However, T cell responses to tumor cells
are often low due to the lack of direct presentation of
modiﬁedpeptidesboundtoclassIImolecules(Figure2).The
formation of class II-peptide complexes is also signiﬁcantly
lower in tumors when compared against professional APCs














Figure 2: Norton and Haque.
partially explain why HLA class II-peptide complexes play
such a limited role in stimulating T cell responses against
tumors. We have demonstrated that the insertion of GILT
in melanoma cells in vitro has the ability to restore CD4+
T cell recognition [11]. Other studies have shown that
CD4+ T cells speciﬁc for select Ags were reduced in animals
lacking the novel enzyme GILT [56]. Collectively, GILT
expression can play an important role in enhancing CD4+
T cell recognition of melanoma cells (Figure 2). However, a
complete understanding of GILT’s role within the HLA class
II pathway has yet to be determined; perhaps may contribute
to the regulation of other factors such as costimulatory or
accessory molecules and intracellular proteases.
6.ImplicationsofGILTinDevisingaWholeCell
Vaccine againstMelanoma
We have previously shown that GILT upregulates Ag pro-
cessing and presentation via the HLA class II pathway
[10, 46], and the regulation of GILT protein expression is
dependent on STAT-1 while independent of CIITA [57]. Our
unpublished data suggest that GILT-expressing melanoma
cells generate more functional epitopes when compared to
non-GILT expressing melanoma. This greater generation of
epitopescouldallowfornotonlyimprovedimmunerecogni-
tion but also the spreading of epitopes to professional APCs
and non-GILT expressing tumor cells, as well as bystander
cells. These professional and nonprofessional APCs as well
as tumors such as melanoma could then be able to present
this repertoire of epitopes to CD4+ T cells, further priming
an immune response and leading to the ablation of tumor
cells.
Successful destruction of melanoma cells would also
require optimum immune recognition and the development
of lasting immune memory. In vivo, melanoma cells express
a multitude of tumor-associated Ags which may be targeted
by T cells through the HLA class II pathway, ultimately
leading to tumor regression. Since these Ags are capable of
stimulating the immune system, tumor samples could be
taken from patients, have GILT expression restored within
these tumor cells, and then given back to patients as a whole
cell vaccine. This whole cell vaccine would allow for a greater
reduction of disulﬁde bonds by the melanoma, an important
diﬀerence from other whole cell vaccines such as Canvaxin
[59]. Also, unlike Canvaxin which uses three allogenic
melanoma lines that express a large number of tumor Ags
[60], our proposed strategy could focus an immune response
against patient speciﬁc tumor Ags expressed by the patient’s
own genetically modiﬁed tumor. This approach could still
take advantage of both cellular and humoral responses while
enhancing the antigen processing and presentation ability
of the genetically modiﬁed melanoma. In this scenario,
GILT expression would upregulate key immune components
such as Ag processing and presentation molecules and
proteases. This upregulation would lead to greater tumor
Ag processing and presentation via the HLA II pathway
(Figure 2). CD4+ T cells would then recognize GILT-
expressing cells and recruit other immune cells and APCs
in order to destroy the tumor cells. The death of the GILT
expressing melanoma would generate a large pool of Ags
and peptides which could then be processed and presented
by professional APCs. After successfully stimulating an
antitumor immune response against the GILT expressing
melanoma, the patient’s melanoma cells, not expressing
GILT, could be recognized by both immune eﬀector cells,
CTLs and NK T cells, and immune regulating CD4+ T
cells; further improving tumor regression. Upon tumor
regression and remission, the patient could be further
protected against any reoccurrence of the melanoma by
a potent antitumor memory response, successfully halting
future disease formation.6 Journal of Oncology
7. Conclusions
Metastatic melanoma is an intricate disease that is extremely
diﬃcult to treat. Novel therapeutic approaches such as
immunotherapy need to be pursued in order to eﬀectively
treat patients with metastatic melanoma. Since metastatic
melanoma cells express a wide variety of tumor associated
Ags, they could be presented to the immune system via
the HLA class II pathway. In this review, we have discussed
previous studies on the molecular and cellular functions
of GILT, and its eﬀect on HLA class II presentation by
melanoma tumors. We have also discussed the implications
of GILT in the development of whole cell vaccines against
metastatic melanoma. Further studies focusing on the eﬀect
of GILT in melanoma, both in vivo and in vitro, need to
be pursued in order to develop successful therapies for use
against metastatic melanoma.
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